Floatz logo

Tisagenlecleucel

B-cell Malignancy

Shanghai Tong Ren HospitalCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the B-cell Malignancy cohort.

Asset / SponsorPhaseRating
ctx110
CRISPR Therapeutics AG
Phase 1/2CC
Eloxatin
BeOne Medicines
Phase 1/2CC
Sonrotoclax
BeOne Medicines
Phase 1/2CC
Mosunetuzumab
BeOne Medicines
Phase 1/2CC
ctx112
CRISPR Therapeutics AG
Phase 1/2CC

View all 10 →

Same molecule, other indications

Tisagenlecleucel is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
Diffuse Large B Cell LymphomaDormant
BB
Indicative ·
64 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →